DRAVP ID  DRAVPc064

Name   Imdevimab

Sequence  Not available

Molecular Formula  Not Available

Condition/Disease  COVID-19

Group  Approved

Type  Antibody

Description  Imdevimab is a monoclonal antibody combined with casirivimab in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. They are reserved for Emergency Use Authorization (EUA) only. In November 2021, the same indication was approved by the EMA.

Active sequence/Structure 

DrugBank Accession Number  DB15940

Pubchem ID  472422363

CHEMBL ID  CHEMBL4650249

UNII  2Z3DQD2JHM

CAS  2415933-40-1

Reference  32540904  32540901